We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+17.96%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$152M
AUM Growth
+$19.6M
Cap. Flow
+$8.22M
Cap. Flow %
5.42%
Top 10 Hldgs %
79.7%
Holding
38
New
3
Increased
11
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$10.4M
2
ADVM
Adverum Biotechnologies
ADVM
+$5.74M
3
TIL icon
Instil Bio
TIL
+$3.82M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$2.44M
5
OKUR
OnKure Therapeutics
OKUR
+$1.42M

Top Sells

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$6.43M
2
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$4.49M
3
LONA
LeonaBio Inc
LONA
+$1.76M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$1.62M
5
ORMP icon
Oramed Pharmaceuticals
ORMP
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 67.15%
2 Technology 1.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGOV icon
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$98.5B
$27.2M 17.93%
270,000
– –
AVIR icon
2
Atea Pharmaceuticals
AVIR
$391M
$22.4M 14.75%
5,536,710
+74,631
+1% +$292K
BIL icon
3
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
$18.4M 12.11%
200,000
– –
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
$11.8M 7.77%
833,117
+377,692
+83% +$5.74M
ACRS icon
5
Aclaris Therapeutics
ACRS
$802M
$11.7M 7.68%
9,395,934
+8,742,827
+1,339% +$10.4M
CYT
6
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$11M 7.25%
3,654,053
+404,045
+12% +$1.25M
CLYM
7
Climb Bio
CLYM
$738M
$6.01M 3.96%
2,193,742
+13,742
+0.6% +$37.8K
TECX
8
Tectonic Therapeutic
TECX
$613M
$5.12M 3.38%
333,469
– –
TIL icon
9
Instil Bio
TIL
$50.3M
$3.77M 2.48%
+348,735
New +$3.82M
OKUR
10
OnKure Therapeutics
OKUR
$168M
$3.62M 2.38%
217,791
+86,368
+66% +$1.42M
CNTB
11
Connect Biopharma Holdings
CNTB
$147M
$3.59M 2.37%
2,061,338
-100
-0% -$122
DSGN icon
12
Design Therapeutics
DSGN
$785M
$3.54M 2.34%
879,478
-150,000
-15% -$401K
LONA
13
LeonaBio Inc
LONA
$67.6M
$2.47M 1.63%
90,000
-55,436
-38% -$1.76M
ORMP icon
14
Oramed Pharmaceuticals
ORMP
$169M
$2.47M 1.63%
844,496
-417,063
-33% -$1.17M
PMVP icon
15
PMV Pharmaceuticals
PMVP
$68.8M
$2.22M 1.46%
+1,306,490
New +$2.44M
ASTC icon
16
Astrotech Corp
ASTC
$15.6M
$1.97M 1.3%
220,410
– –
WING icon
17
PUT
Wingstop
WING
$3.9B
$1.83M 1.21%
800
-100
-11% -$31.1K
LENZ
18
LENZ Therapeutics
LENZ
$162M
$1.43M 0.94%
63,916
-1
-0% -$21
KNTE
19
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.33M 0.88%
498,851
+30,641
+7% +$75.9K
ORKA
20
Oruka Therapeutics
ORKA
$5.72B
$1.24M 0.82%
58,911
– –
FBRX icon
21
Forte Biosciences
FBRX
$1.01B
$1.23M 0.81%
70,468
– –
MIST icon
22
Milestone Pharmaceuticals
MIST
$148M
$1.08M 0.72%
606,145
+163,793
+37% +$266K
VRCA icon
23
Verrica Pharmaceuticals
VRCA
$96.4M
$1.07M 0.7%
18,000
– –
LSTA icon
24
Lisata Therapeutics
LSTA
$31.8M
$888K 0.59%
284,669
+14,830
+5% +$43.9K
ELVN icon
25
Enliven Therapeutics
ELVN
$3.78B
$881K 0.58%
50,100
+100
+0.2% +$1.53K
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
TI
Truxt Investmentos Rio De Janeiro, Brazil $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
HCWM
Hidden Cove Wealth Management Bainbridge Island, Washington $156M AUM 16.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

BML Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, BML Capital Management held 38 positions worth $152M, up 15% from $132M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

BML Capital Management deployed $8.22M of net new capital in Q1 2024, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was Instil Bio: 348,735 shares worth $3.77M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 60% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was LeonaBio Inc, an estimated $1.76M trimmed.

  • BML Capital Management's largest Q1 2024 buy was Instil Bio: 348,735 shares worth $3.77M.
  • BML Capital Management added most to Aclaris Therapeutics in Q1 2024, an estimated $10.4M increase.
  • BML Capital Management's biggest Q1 2024 reduction was LeonaBio Inc, cutting an estimated $1.76M.
  • BML Capital Management fully exited Tourmaline Bio in Q1 2024, selling an estimated $6.43M.
  • BML Capital Management's ten largest holdings make up 80% of its $152M portfolio in Q1 2024.
  • BML Capital Management opened 3 new positions and closed 6 in Q1 2024.
  • BML Capital Management's portfolio value rose 15% quarter-over-quarter to $152M.

Based on BML Capital Management's 13F filing for Q1 2024, filed 23 Apr 2024.